Proscia, a Philadelphia, PA-based provider of digital and computational pathology solutions, raised $37M in Series C funding.
The round was led by Highline Capital Management, Triangle Peak Partners, and Alpha Intelligence Capital with participation from Scale Venture Partners, Hitachi Ventures, ROBO Global, Emerald Development Managers, and Razor’s Edge Ventures.
The company intends to use the funds
- to accelerate adoption of computational pathology, strengthening its market and product leadership,
- to scale its commercial operations,
- to expand its sales, marketing, and support teams, as well as
- to grow distribution partnerships following its recent OEM agreement with Siemens Healthineers.
Led by CEO David West, Proscia is a software company that provides a Concentriq® platform, which combines enterprise scalability with a broad portfolio of AI applications to accelerate breakthroughs and unlock clinical insights that advance precision medicine.
Proscia’s user base includes 10 of the top 20 pharmaceutical companies as well as the Joint Pathology Center, which selected Concentriq to digitize a large human tissue repository of over 55 million slides.
FinSMEs
14/06/2022